Welcome to our dedicated page for Envveno Med SEC filings (Ticker: NVNBW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NVNBW SEC filings page on Stock Titan aggregates regulatory documents connected to ENVVENO MEDICAL CP WT 26 and its underlying issuer, enVVeno Medical Corporation. These filings, drawn from the SEC’s EDGAR system, include Forms 8-K, Definitive Proxy Statements on Schedule 14A, and references to shelf registration statements and prospectus supplements. Together, they provide a detailed record of how the company reports material events, stockholder actions, capital raising arrangements, and regulatory developments.
Form 8-K filings from 2025 illustrate several important themes. One 8-K dated October 10, 2025 discloses a Nasdaq notice that the company’s common stock no longer met the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market, and explains the 180-day compliance period, possible additional 180-day extension, and the potential role of a reverse stock split in curing the deficiency. Later 8-K filings dated December 12, 2025 report the results of the 2025 Annual Meeting of Stockholders, including director elections, an advisory vote on executive compensation, ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, the rejection of the 2025 Equity Incentive Plan, and stockholder authorization for the Board of Directors to implement a reverse stock split within a specified ratio range.
Another 8-K dated October 30, 2025 describes an At-the-Market Offering Agreement with Ladenburg Thalmann & Co. Inc., under which the company may sell shares of its common stock from time to time as at-the-market equity offerings pursuant to an effective Form S-3 registration statement and a filed prospectus supplement. This filing also lists related exhibits, including the agreement itself and a legal opinion on the validity of the shares. An 8-K dated November 20, 2025 details an amendment to the company’s Amended and Restated Bylaws, revising the quorum requirement for stockholder meetings to a specified percentage of voting power, subject to applicable law and charter provisions.
Regulatory and product matters appear in an 8-K dated November 13, 2025, which reports that the company issued a press release about an unfavorable FDA appeal decision on its Premarket Approval application for VenoValve®, described as a surgical replacement venous valve for treating severe deep chronic venous insufficiency. The company notes that the press release is furnished as an exhibit, and the related Definitive Proxy Statement discusses a broader appeal process and its implications for both VenoValve and enVVe, a next generation transcatheter replacement venous valve.
On this NVNBW filings page, Stock Titan presents these documents with AI-powered summaries that help explain the significance of each filing. Investors can quickly see how stockholder votes affected equity incentive plans and reverse stock split authority, how the company structures at-the-market equity offerings, and how listing compliance issues and FDA-related outcomes are disclosed. The page also surfaces information relevant to monitoring governance practices, auditor relationships, bylaw changes, and other material events reported by enVVeno Medical Corporation in connection with the security associated with NVNBW.
enVVeno Medical Corporation files its annual report detailing a major strategic pivot after its surgically implanted VenoValve received a not-approvable letter from the FDA in August 2025 and a subsequent appeal was denied. The company is now concentrating on the enVVe System, a first-in-class, non-surgical, transcatheter replacement venous valve for severe chronic venous insufficiency, and has completed pre-clinical testing while beginning FDA discussions for a pivotal trial expected to start in 2026. enVVeno highlights that it has no product revenue, has incurred significant losses since inception, and may never achieve profitability without successful regulatory approval and commercialization of enVVe or future devices. The filing emphasizes substantial clinical, regulatory, manufacturing, reimbursement and financing risks, reliance on a small supplier base for porcine tissue and components, and the need for additional capital to continue development. As of June 30, 2025, non-affiliate common equity market value was $76.1 million, and as of March 24, 2026, there were 655,521 shares of common stock outstanding and 33 full-time employees.
enVVeno Medical Corp director Francis Duhay reported an open-market sale of 140 shares of Common Stock at a weighted-average price of $11.5224 per share. The sale was completed under a pre-arranged Rule 10b5-1 trading plan adopted in June 2025. Following this transaction, Duhay directly holds 2,502 shares of enVVeno Medical common stock.
Northstrive Fund II LP and Braeden Lichti filed a Schedule 13D on enVVeno Medical Corp after accumulating a 5.05% stake in its common stock. As of February 10, 2026, Lichti beneficially owned 33,151 shares, based on 655,606 shares outstanding as of January 20, 2026.
The investors sent a letter to enVVeno’s board recommending an immediate halt to all clinical operations and a formal strategic review. Their suggestions include returning capital to shareholders or pursuing a merger or reverse merger to preserve cash and limit further dilution, while reserving the right to increase or reduce their position.
Northstrive Fund II LP and Braeden Lichti have filed a Schedule 13D on enVVeno Medical Corp, shifting from a passive to an active investor stance. They report beneficial ownership of 33,151 common shares, representing 5.05% of enVVeno’s outstanding stock as of January 20, 2026.
The investors sent a letter to the company’s board on February 20, 2026 urging the board to immediately halt all clinical operations and begin a formal strategic review. Their recommendations include considering returning capital to shareholders or pursuing a merger or reverse merger to maximize shareholder value while preserving cash and limiting further dilution.
Perceptive Advisors LLC and related investors filed an amended ownership report showing beneficial ownership of 2,048,515 shares of enVVeno Medical Corporation common stock, representing 9.99% of the company. The stake is held through Perceptive Life Sciences Master Fund, which owns common shares and warrants.
The Master Fund directly holds 1,759,035 shares plus 861,192 warrants exercisable at $8.334 per share, but a 9.99% beneficial ownership limitation currently allows exercise of only 289,480 warrants. Perceptive Advisors is the investment manager and Joseph Edelman is its managing member.
Braeden Lichti and Northstrive Fund II LP have disclosed significant ownership stakes in enVVeno Medical Corp. Lichti reports beneficial ownership of 33,151 shares of common stock, representing 5.05% of the company, while Northstrive Fund II LP reports 20,129 shares, or 3.07%.
The percentages are based on 655,606 shares of enVVeno Medical Corp common stock issued and outstanding as of January 20, 2026, as reported by the company. Lichti, a Canadian citizen, is the manager of Northstrive Fund II LP, a Delaware entity, and holds both sole and shared voting and dispositive power over different portions of the shares.
enVVeno Medical Corporation received a Schedule 13G filing showing that investor Braeden Lichti beneficially owns 33,151 shares of common stock, representing 5.05% of the company. This total includes 13,022 shares over which he has sole voting and dispositive power.
Lichti also shares voting and dispositive power over 20,129 shares held through Northstrive Fund II LP, which separately reports beneficial ownership of those 20,129 shares, or 3.07% of the common stock. Percentages are based on 655,606 shares outstanding as of January 20, 2026.
enVVeno Medical Corporation reported that as of December 31, 2025, it held a cash and investments balance of approximately $28 million, highlighting its available liquidity at year end. The company also announced that it has regained compliance with the minimum bid price requirement and all other criteria for continued listing on The NASDAQ Stock Market, removing an immediate risk to its exchange listing. The announcement was made through a press release furnished as an exhibit to this report.
enVVeno Medical Corporation implemented a one-for-thirty-five reverse stock split of its common stock, effective January 20, 2026. Every 35 previously issued and outstanding shares were automatically combined into one share, with no change to the par value.
No fractional shares were issued; any fractional positions were rounded up to the nearest whole share. The number of common shares outstanding decreased from 22,946,223 to 655,606, while authorized common shares remain at 250,000,000.
The company proportionally adjusted outstanding stock options and warrants so that share amounts decreased by a factor of 35 and exercise prices increased by a factor of 35, preserving their overall economic value. The stock now trades on a reverse split-adjusted basis on Nasdaq under the symbol NVNO.